● BREAKING NEWS
HealthBiz
search
Menu
Policy / Regulations Nov 05, 2026 · min read

Drug Licence Suspension New Rules For NSQ India

Team HealthBiz

HealthBiz

Drug Licence Suspension New Rules For NSQ India

New Delhi, November 5, 2026: The Union Ministry of Health and Family Welfare has proposed stricter regulatory measures to strengthen pharmaceutical quality control in India, including the immediate suspension of manufacturing licences for medicines that fail specified critical quality tests.

The proposed amendments to the Drugs Rules, 1945, aim to enable faster regulatory action against pharmaceutical manufacturers whose products are declared Not of Standard Quality (NSQ) following government laboratory testing.

Under the proposed framework, licensing authorities would be empowered to immediately suspend the manufacturing licence for the concerned drug if a Government Analyst's report identifies failures in any of five critical parameters: assay, dissolution, related substances, impurities or sterility.

These parameters are essential for evaluating a medicine's active ingredient content, drug-release characteristics, impurity levels and microbiological safety.

Proposed Changes to Existing Drug Licensing Procedures

Currently, the suspension or cancellation of a pharmaceutical manufacturing licence involves prescribed regulatory procedures, including the issuance of a show-cause notice.

According to the Health Ministry, these procedures can create a time gap between the identification of a substandard medicine and the initiation of regulatory action. During this period, affected medicines may continue to remain in circulation, potentially increasing patient safety risks and complicating product recalls.

The proposed amendments seek to address this regulatory gap by enabling licensing authorities to take immediate action following an adverse Government Analyst report.

Manufacturers Must Complete Corrective Actions Before Licence Restoration

The draft rules also establish stricter conditions for restoring suspended manufacturing licences.

Manufacturers would be required to conduct an effective Root Cause Analysis (RCA) to identify the reasons behind the quality failure and implement appropriate Corrective and Preventive Actions (CAPA).

The suspension would remain in force until the concerned licensing authority is satisfied that the necessary corrective measures have been implemented and independently verified.

This provision is intended to ensure that manufacturers address underlying quality-control deficiencies rather than merely correcting isolated product failures.

Strengthening Regulatory Reporting and Accountability

The Ministry has also proposed amendments to Form 13, which relates to Government Analyst test reports.

Under the proposed reporting mechanism, test reports identifying medicines as Not of Standard Quality would be shared with:

  • Drugs Controller General of India (DCGI).

  • Relevant State or Union Territory Licensing Authority.

  • Concerned pharmaceutical manufacturer.

  • Marketer of the affected medicine.

The enhanced reporting mechanism is expected to improve coordination between central and state drug regulators while strengthening accountability across the pharmaceutical manufacturing and marketing chain.

Background: Growing Focus on Pharmaceutical Quality Standards

India's pharmaceutical manufacturing sector has faced increased domestic and international scrutiny over medicine quality and manufacturing standards.

Concerns have intensified following incidents involving contaminated cough syrups manufactured in India that were linked to child deaths in India, The Gambia and Uzbekistan during 2022–2023.

The proposed regulatory changes also follow deliberations at the 65th meeting of the Drugs Consultative Committee held on December 20, 2024, and recommendations made during the 92nd meeting of the Drugs Technical Advisory Board on April 24, 2025.

Public Consultation Invited

The Health Ministry has notified the draft amendments for public consultation and invited objections and suggestions from stakeholders and members of the public within 30 days from the date the relevant Gazette notification becomes available.

The proposed amendments are not yet final rules. They will take effect following their final publication in the Official Gazette.

If implemented, the changes could strengthen India's post-marketing drug surveillance framework, accelerate regulatory intervention against substandard medicines and reinforce patient safety across the pharmaceutical supply chain.

Source: Ministry of Health and Family Welfare, Government of India; Reuters.

Category: Healthcare Policy & Regulation

Tags: Drug Regulation, CDSCO, DCGI, Pharmaceutical Industry, Drug Quality Control, Drugs Rules 1945, Patient Safety, Pharma Manufacturing, Government Policy

Written by

Team HealthBiz